Smart Trade Insights
  • Business
  • Economy
  • Investing
  • Politics
Top Posts
Questcorp Mining Continues Exploration in Advance of Drilling...
Canadian Investment Regulatory Organization Trade Resumption – STUD
Bringing Art, Youth, and Football Together: Kobo’s Workshop...
FPX Nickel Receives Multi-Year Area-BasedPermit and Commences 2025...
Asara Resources
New Age Exploration
Finlay Minerals Ltd. engages Investing News Network
Corporate Update
Crypto Market Recap: SEC Issues Crypto ETF Guidance,...
Top 5 Junior Gold Mining Stocks on the...
  • Business
  • Economy
  • Investing
  • Politics

Smart Trade Insights

Investing

FDA Fast Track Designation for Narmafotinib in Advanced Pancreatic Cancer

by admin September 20, 2024
September 20, 2024
FDA Fast Track Designation for Narmafotinib in Advanced Pancreatic Cancer

Amplia Therapeutics Limited (ASX: ATX), (“Amplia” or the “Company”), is pleased to announce that the United States Food and Drug Administration (FDA) has granted Fast Track Designation to Amplia’s Focal Adhesion Kinase inhibitor, narmafotinib, for the treatment of advanced pancreatic cancer.

HIGHLIGHTS

The US FDA has granted Fast Track Designation to Amplia’s lead drug narmafotinib in advanced pancreatic cancerFast Track Designation facilitates the development of investigational drugs and allows for expedited review

Fast Track Designation is available to drugs that may provide an advantage over current therapies in the treatment of serious conditions. It is designed to speed the development of these drugs to enable patients to receive them sooner. This Designation will grant the Company access to more frequent meetings, and written communication, with the FDA. In future, narmafotinib may be eligible for Accelerated Approval and Priority Review. The Company has previously received Orphan Drug Designation from the FDA for narmafotinib in pancreatic cancer.

The Company’s CEO and Managing Director, Dr Chris Burns, commented, “Fast Track Designation for narmafotinib is a significant milestone for the Company. With this designation, we can work more closely with the FDA to accelerate our clinical program and gather the most compelling evidence for regulatory approval in this devastating disease.”

Amplia’s clinical trial in advanced pancreatic cancer, the ACCENT trial, is ongoing in Australia and South Korea. Earlier this year, the Company announced that the US FDA had cleared its IND1 application for a trial of narmafotinib in pancreatic cancer in the US. This trial is in advanced planning stages.

This ASX announcement was approved and authorised for release by the Board of Amplia Therapeutics.

Click here for the full ASX Release

This post appeared first on investingnews.com

previous post
Saskatchewan Research Council Achieves Commercial Production at Rare Earths Facility
next post
Lithium Universe Limited (ASX: LU7) – Trading Halt

You may also like

Brightstar Resources Limited (ASX: BTR) – Reinstatement to...

October 29, 2024

Results of Entitlement Issue

August 9, 2024

Uranium Price Update: Q1 2025 in Review

April 24, 2025

BTR accelerates Second Fortune high-grade mine development

December 5, 2024

Rua Gold Acquires Siren Gold’s Reefton Assets for...

November 28, 2024

Strong Momentum Continuing at Flicka Lake Gold and...

December 2, 2024

World Copper Announces Corporate Update Webinar

August 24, 2024

Top 10 Iron Ore-producing Countries (Updated 2024)

November 5, 2024

Crypto Market Recap: Institutional Investments, Stablecoin News and...

June 20, 2025

5 Top Weekly TSXV Stocks: Gold Stocks Lead...

August 12, 2024

    Fill Out & Get More Relevant News


    Stay ahead of the market and unlock exclusive trading insights & timely news. We value your privacy - your information is secure, and you can unsubscribe anytime. Gain an edge with hand-picked trading opportunities, stay informed with market-moving updates, and learn from expert tips & strategies.

    Recent Posts

    • Questcorp Mining Continues Exploration in Advance of Drilling at the La Union Gold & Silver Project in Mexico

      July 8, 2025
    • Canadian Investment Regulatory Organization Trade Resumption – STUD

      July 8, 2025
    • Bringing Art, Youth, and Football Together: Kobo’s Workshop in Kossou

      July 8, 2025
    • FPX Nickel Receives Multi-Year Area-BasedPermit and Commences 2025 Drilling Activities at Baptiste Nickel Project

      July 8, 2025
    • Asara Resources

      July 8, 2025
    Promotion Image

    banner ads

    Categories

    • Business (757)
    • Economy (829)
    • Investing (2,360)
    • Politics (737)
    • Privacy Policy
    • Terms & Conditions

    Disclaimer: smarttradeinsights.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.


    Copyright © 2025 smarttradeinsights.com | All Rights Reserved